DCMIC
ALBO

Decheng Capital Management III (Cayman)’s Albireo Pharma Inc ALBO Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-623,342
Closed -$13.5M – 26
2022
Q4 		$13.5M Hold
623,342
– – 5.04% 7
2022
Q3 		$12.1M Buy
623,342
+105,000
+20% +$2.17M 4.38% 7
2022
Q2 		$10.3M Hold
518,342
– – 3.9% 7
2022
Q1 		$15.5M Buy
+518,342
New +$15.2M 4.74% 6

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s ALBO Position: Q1 2023 in Review

Decheng Capital Management III (Cayman) sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 623,342 shares — an estimated $13.5M sold.

Decheng Capital Management III (Cayman) first reported a position in ALBO in Q1 2022 and held it in 4 quarters. The position peaked at $15.5M in Q1 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Decheng Capital Management III (Cayman) reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Decheng Capital Management III (Cayman) sold 623,342 Albireo Pharma Inc shares in Q1 2023, an estimated $13.5M.
  • Decheng Capital Management III (Cayman) first reported a position in Albireo Pharma Inc in Q1 2022 and held it in 4 quarters.
  • Decheng Capital Management III (Cayman)'s Albireo Pharma Inc position peaked at $15.5M in Q1 2022.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q1 2023, filed 10 May 2023.